HEADER TRANSFERASE 06-NOV-22 8BJU TITLE HUMAN WEE1 KINASE IN COMPLEX WITH INHIBITOR 1-[6-(1-HYDROXY-1-METHYL- TITLE 2 ETHYL)-PYRIDIN-2-YL]-2-(2-METHOXY-PHENYL)-6-[4-(4-METHYL-PIPERAZIN-1- TITLE 3 YL)-PHENYLAMINO]-1,2-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPND MOL_ID: 1; COMPND 2 MOLECULE: WEE1-LIKE PROTEIN KINASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: WEE1HU,WEE1A KINASE; COMPND 5 EC: 2.7.10.2; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: WEE1; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS WEE1, KINASE, PROTEIN-INHIBITOR COMPLEX, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR D.MUSIL,R.LAN REVDAT 2 07-FEB-24 8BJU 1 REMARK REVDAT 1 31-MAY-23 8BJU 0 JRNL AUTH S.GULER,M.C.DIPOTO,A.CRESPO,R.CALDWELL,B.DOERFEL, JRNL AUTH 2 N.GROSSMANN,K.HO,B.HUCK,C.C.JONES,R.LAN,D.MUSIL,J.POTNICK, JRNL AUTH 3 H.SCHILKE,B.SHERER,S.SIMON,C.SIRRENBERG,Z.ZHANG, JRNL AUTH 4 L.LIU-BUJALSKI JRNL TITL SELECTIVE WEE1 INHIBITORS LED TO ANTITUMOR ACTIVITY IN VITRO JRNL TITL 2 AND CORRELATED WITH MYELOSUPPRESSION. JRNL REF ACS MED.CHEM.LETT. V. 14 566 2023 JRNL REFN ISSN 1948-5875 JRNL PMID 37197456 JRNL DOI 10.1021/ACSMEDCHEMLETT.2C00481 REMARK 2 REMARK 2 RESOLUTION. 1.53 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.53 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 21.25 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 84.1 REMARK 3 NUMBER OF REFLECTIONS : 35957 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.223 REMARK 3 R VALUE (WORKING SET) : 0.221 REMARK 3 FREE R VALUE : 0.263 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.660 REMARK 3 FREE R VALUE TEST SET COUNT : 1675 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 51 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.53 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.58 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 720 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.3187 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 691 REMARK 3 BIN R VALUE (WORKING SET) : 0.3171 REMARK 3 BIN FREE R VALUE : 0.3589 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.03 REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2070 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 42 REMARK 3 SOLVENT ATOMS : 206 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 34.13 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.15050 REMARK 3 B22 (A**2) : 0.57590 REMARK 3 B33 (A**2) : -0.42540 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.250 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.112 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.112 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.107 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.109 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.954 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.931 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2212 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 2994 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 787 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 374 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2212 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 274 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2159 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.011 REMARK 3 BOND ANGLES (DEGREES) : 1.00 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.43 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 15.56 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: { A|* } REMARK 3 ORIGIN FOR THE GROUP (A): -12.3138 -1.2849 14.0050 REMARK 3 T TENSOR REMARK 3 T11: 0.0296 T22: 0.0727 REMARK 3 T33: -0.0563 T12: 0.1434 REMARK 3 T13: 0.0529 T23: 0.0551 REMARK 3 L TENSOR REMARK 3 L11: 0.7494 L22: 1.3867 REMARK 3 L33: 0.3114 L12: 0.0954 REMARK 3 L13: 0.3547 L23: -0.1685 REMARK 3 S TENSOR REMARK 3 S11: 0.0104 S12: -0.0198 S13: 0.0346 REMARK 3 S21: -0.1991 S22: -0.1752 S23: -0.1105 REMARK 3 S31: 0.0349 S32: -0.0202 S33: 0.1648 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 8BJU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 14-NOV-22. REMARK 100 THE DEPOSITION ID IS D_1292126512. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 13-FEB-19 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.75 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06SA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.99989 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 36028 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.530 REMARK 200 RESOLUTION RANGE LOW (A) : 117.570 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 84.1 REMARK 200 DATA REDUNDANCY : 8.100 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.53 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.62 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : 7.60 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 2IO6 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.91 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.15 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 6.0 % W/V PEG6000, 0.10M MES PH 4.75, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 23.31100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 58.78500 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 25.28850 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 58.78500 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 23.31100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 25.28850 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 291 REMARK 465 LYS A 292 REMARK 465 THR A 437 REMARK 465 SER A 438 REMARK 465 ILE A 439 REMARK 465 PRO A 440 REMARK 465 ASN A 441 REMARK 465 ALA A 442 REMARK 465 ALA A 443 REMARK 465 SER A 444 REMARK 465 GLU A 445 REMARK 465 GLU A 446 REMARK 465 GLY A 447 REMARK 465 ASP A 448 REMARK 465 GLU A 449 REMARK 465 ASP A 450 REMARK 465 ASP A 451 REMARK 465 TRP A 452 REMARK 465 ALA A 453 REMARK 465 SER A 454 REMARK 465 ASN A 455 REMARK 465 ALA A 572 REMARK 465 SER A 573 REMARK 465 ARG A 574 REMARK 465 LYS A 575 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 303 131.13 -173.78 REMARK 500 ASP A 426 37.03 -150.66 REMARK 500 ASP A 463 76.95 57.17 REMARK 500 SER A 472 69.64 -150.80 REMARK 500 ASN A 519 -174.63 -170.25 REMARK 500 PRO A 535 48.51 -83.70 REMARK 500 REMARK 500 REMARK: NULL DBREF 8BJU A 291 575 UNP P30291 WEE1_HUMAN 291 575 SEQRES 1 A 285 MET LYS SER ARG TYR THR THR GLU PHE HIS GLU LEU GLU SEQRES 2 A 285 LYS ILE GLY SER GLY GLU PHE GLY SER VAL PHE LYS CYS SEQRES 3 A 285 VAL LYS ARG LEU ASP GLY CYS ILE TYR ALA ILE LYS ARG SEQRES 4 A 285 SER LYS LYS PRO LEU ALA GLY SER VAL ASP GLU GLN ASN SEQRES 5 A 285 ALA LEU ARG GLU VAL TYR ALA HIS ALA VAL LEU GLY GLN SEQRES 6 A 285 HIS SER HIS VAL VAL ARG TYR PHE SER ALA TRP ALA GLU SEQRES 7 A 285 ASP ASP HIS MET LEU ILE GLN ASN GLU TYR CYS ASN GLY SEQRES 8 A 285 GLY SER LEU ALA ASP ALA ILE SER GLU ASN TYR ARG ILE SEQRES 9 A 285 MET SER TYR PHE LYS GLU ALA GLU LEU LYS ASP LEU LEU SEQRES 10 A 285 LEU GLN VAL GLY ARG GLY LEU ARG TYR ILE HIS SER MET SEQRES 11 A 285 SER LEU VAL HIS MET ASP ILE LYS PRO SER ASN ILE PHE SEQRES 12 A 285 ILE SER ARG THR SER ILE PRO ASN ALA ALA SER GLU GLU SEQRES 13 A 285 GLY ASP GLU ASP ASP TRP ALA SER ASN LYS VAL MET PHE SEQRES 14 A 285 LYS ILE GLY ASP LEU GLY HIS VAL THR ARG ILE SER SER SEQRES 15 A 285 PRO GLN VAL GLU GLU GLY ASP SER ARG PHE LEU ALA ASN SEQRES 16 A 285 GLU VAL LEU GLN GLU ASN TYR THR HIS LEU PRO LYS ALA SEQRES 17 A 285 ASP ILE PHE ALA LEU ALA LEU THR VAL VAL CYS ALA ALA SEQRES 18 A 285 GLY ALA GLU PRO LEU PRO ARG ASN GLY ASP GLN TRP HIS SEQRES 19 A 285 GLU ILE ARG GLN GLY ARG LEU PRO ARG ILE PRO GLN VAL SEQRES 20 A 285 LEU SER GLN GLU PHE THR GLU LEU LEU LYS VAL MET ILE SEQRES 21 A 285 HIS PRO ASP PRO GLU ARG ARG PRO SER ALA MET ALA LEU SEQRES 22 A 285 VAL LYS HIS SER VAL LEU LEU SER ALA SER ARG LYS HET QT9 A 601 42 HETNAM QT9 2-(2-METHOXYPHENYL)-6-[[4-(4-METHYLPIPERAZIN-1-YL) HETNAM 2 QT9 PHENYL]AMINO]-1-[6-(2-OXIDANYLPROPAN-2-YL)PYRIDIN-2- HETNAM 3 QT9 YL]PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE FORMUL 2 QT9 C31 H34 N8 O3 FORMUL 3 HOH *206(H2 O) HELIX 1 AA1 SER A 293 GLU A 298 1 6 HELIX 2 AA2 SER A 337 LEU A 353 1 17 HELIX 3 AA3 SER A 383 ILE A 394 1 12 HELIX 4 AA4 LYS A 399 MET A 420 1 22 HELIX 5 AA5 LYS A 428 SER A 430 5 3 HELIX 6 AA6 ASP A 463 VAL A 467 5 5 HELIX 7 AA7 ALA A 484 GLN A 489 1 6 HELIX 8 AA8 HIS A 494 ALA A 511 1 18 HELIX 9 AA9 ASN A 519 GLN A 528 1 10 HELIX 10 AB1 SER A 539 ILE A 550 1 12 HELIX 11 AB2 ASP A 553 ARG A 557 5 5 HELIX 12 AB3 SER A 559 LYS A 565 1 7 HELIX 13 AB4 HIS A 566 SER A 571 1 6 SHEET 1 AA1 5 PHE A 299 GLY A 308 0 SHEET 2 AA1 5 GLY A 311 LYS A 318 -1 O LYS A 315 N LEU A 302 SHEET 3 AA1 5 ILE A 324 LYS A 331 -1 O TYR A 325 N CYS A 316 SHEET 4 AA1 5 HIS A 371 GLU A 377 -1 O ASN A 376 N ALA A 326 SHEET 5 AA1 5 TYR A 362 GLU A 368 -1 N SER A 364 O GLN A 375 SHEET 1 AA2 2 LEU A 422 VAL A 423 0 SHEET 2 AA2 2 THR A 468 ARG A 469 -1 O THR A 468 N VAL A 423 SHEET 1 AA3 2 ILE A 432 SER A 435 0 SHEET 2 AA3 2 MET A 458 ILE A 461 -1 O LYS A 460 N PHE A 433 CRYST1 46.622 50.577 117.570 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021449 0.000000 0.000000 0.00000 SCALE2 0.000000 0.019772 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008506 0.00000